Released Nov 9, 2026, after the close
10-Q filed Nov 9, 2026, 40 days after period end · 0001193125-26-453872
On November 9, 2026, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the three and nine months ended September 30, 2026.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $1.71M | $0.00 | $0.00 | — |
| Net Income | -$7.73M | -$5.41M | -$6.78M |
Rani Therapeutics Holdings, Inc. · CIK 1856725 · Engraved from SEC EDGAR
| -$9.20M |
| EPS Diluted | -$0.04 | -$0.12 | -$0.24 | -$0.36 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cash, cash equivalents and marketable securities totaled $45.3 million as of September 30, 2026, compared to $53.4 million as of June 30, 2026.¶2
Contract revenue was $1.7 million for the three months ended September 30, 2026, with net loss of $8.8 million compared to $7.9 million a year earlier.¶3¶4¶5
Rani expects its cash, cash equivalents and marketable securities to be sufficient to fund operations at least through the end of 2027.¶2¶6
In October 2026, Rani announced that the RaniPill Capsule platform technology was accepted into the U.S. FDA Emerging Technology Program (ETP).¶7
Participant enrollment continues in the Phase 1a expansion cohort of RT-114, with additional data expected by the end of 2026.¶8